Reneo Pharmaceuticals, Inc. (RPHM)
NASDAQ: RPHM · IEX Real-Time Price · USD
5.58
+0.16 (2.95%)
Mar 29, 2023, 4:30 PM EDT - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|
Selling, General & Admin | 16.14 | 11.65 | 3.61 | 2.38 |
Research & Development | 37.71 | 28.17 | 15.94 | 13.1 |
Operating Expenses | 53.85 | 39.82 | 19.55 | 15.47 |
Operating Income | -53.85 | -39.82 | -19.55 | -15.47 |
Other Expense / Income | -1.89 | -0.05 | -0.09 | -3.04 |
Pretax Income | -51.96 | -39.77 | -19.47 | -12.44 |
Net Income | -51.96 | -39.77 | -19.47 | -12.44 |
Shares Outstanding (Basic) | 24 | 18 | 2 | 2 |
Shares Outstanding (Diluted) | 24 | 18 | 2 | 2 |
Shares Change | 35.01% | 794.56% | 4.11% | - |
EPS (Basic) | -2.12 | -2.19 | -9.60 | -6.38 |
EPS (Diluted) | -2.12 | -2.19 | -9.60 | -6.38 |
Free Cash Flow Per Share | -1.95 | -2.10 | -9.15 | -6.42 |
EBITDA | -51.43 | -39.72 | -19.43 | -12.4 |
Depreciation & Amortization | 0.53 | 0.05 | 0.04 | 0.03 |
EBIT | -51.96 | -39.77 | -19.47 | -12.44 |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).